$AVTR · Avantor, Inc.
Avantor reported Q3 FY2026 results with net sales of $1,698.3M, up 4.6% year-over-year (5.2% organic). GAAP diluted EPS swung to $0.30 from -$1.04 in the prior-year quarter, which had included a $785M goodwill impairment. Adjusted EPS was flat at $0.22. The company raised its full-year 2026 guidance for organic revenue growth, adjusted EPS, and free cash flow.
- Net sales of $1,698.3M, up 4.6% reported and 5.2% organic vs. Q3 2025
- GAAP diluted EPS of $0.30 vs. -$1.04 in prior year; adjusted EPS flat at $0.22
- VWR Distribution & Services organic growth accelerated to 5.8%; Bioscience & Medtech returned to 3.6% organic growth
- Free cash flow of $156.2M for the quarter; adjusted net leverage improved to 3.1x
- FY 2026 organic revenue growth guidance raised to +0.75% to +1.25% from -0.5% to +0.5%
Markets closed — no regular-session reaction yet; extended-hours move not captured here. Prior-year Q3 included a $785M goodwill impairment that drove a GAAP net loss of $711.8M, making the return to $203.4M net income a stark headline swing.
Avantor's return to organic growth and guidance raise mark a potential inflection after a prolonged post-pandemic normalization, with both business segments now expanding.
Avantor's return to organic growth across both segments signals improving end-market demand in life sciences tools, a sector that has been navigating a post-pandemic normalization. The guidance raise suggests management sees sustained momentum.
Adjusted operating income margin in VWR Distribution declined year-over-year due to unfavorable product mix and higher SG&A expenses. GAAP net leverage remains elevated at 9.6x, though adjusted net leverage is 3.1x.